Journal List > Korean J Urol > v.50(2) > 1005274

Korean J Urol. 2009 Feb;50(2):148-153. Korean.
Published online February 25, 2009.  https://doi.org/10.4111/kju.2009.50.2.148
Copyright © The Korean Urological Association, 2009
Comparison of the Efficacy of a Terpene Mixture and Alpha-Blocker for Treatment of Category III Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study
Woo Heon Cha, Ki Ho Kim and Young Jin Seo
Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea.

Correspondence to: Young Jin Seo. Department of Urology, College of Medicine, Dongguk University, 1090-1, Seokjang-dong, Gyeongju 780-350, Korea. TEL: 054-770-8265, FAX: 054-771-0769, Email: seoyjin@korea.co
Received August 04, 2008; Accepted September 08, 2008.

Abstract

Purpose

The aim of this study was to evaluate the efficacy of a terpene mixture compared with alpha-blocker in patients with chronic pelvic pain syndrome (CPPS).

Materials and Methods

Patients diagnosed with CPPS were included in this study. The patients were randomly placed into three groups. Group 1 was treated with levofloxacin alone (36 patients), group 2 was treated with levofloxacin and alfuzosin (33 patients), and group 3 was treated with levofloxacin and terpene mixture (34 patients) for 8 weeks. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) was evaluated in patients in each group at the beginning of the study and after 8 weeks of treatment.

Results

Pain domain, urinary domain, quality of life domain, and total score on the NIH-CPSI were not significantly different at the initial visit. After treatment with each medication, improvements on the pain domain and total score of the NIH-CPSI were better in group 3 than in group 1 or group 2 (p<0.05). Improvement on the urinary domain of the NIH-CPSI was better in group 2 than in group 1 or group 3 (p=0.014). Changes in the quality of life domain of the NIH-CPSI were not significant among the three groups.

Conclusions

This study suggests that the terpene mixture and alpha-blockers may have significant benefit for symptomatic relief, especially in the pain and urinary domains, respectively.

Keywords: Pelvic pain; Adrenergic alpha-antagonists; Terpenes

Figures


Fig. 1
Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) pain domain score (potential of 21 points) at the beginning of the study and after 8 weeks of treatment in each group.
Click for larger image


Fig. 2
Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) urinary domain score (potential of 10 points) at the beginning of the study and after 8 weeks of treatment in each group.
Click for larger image


Fig. 3
Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life domain score (potential of 12 points) at the beginning of the study and after 8 weeks of treatment in each group.
Click for larger image


Fig. 4
Mean value of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score (potential of 43 points) at the beginning of the study and after 8 weeks of treatment in each group.
Click for larger image

Tables


Table 1
Baseline patient characteristics
Click for larger image

References
1. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581–589.
2. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236–237.
3. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first national institutes of health international prostatitis collaborative network. Urology 1999;54:229–233.
4. Lee CB, Ha US, Lee SJ, Kim SW, Cho YH. Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2006;24:55–60.
5. Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol 2007;178:2411–2415.
6. Woo YN. Prostatitis. Korean J Urol 1994;35:575–585.
7. Kirby RS. Surgical considerations in the management of prostatitis. In: Nickel JC, editor. Textbook of prostatitis. Oxford: ISIS Medical Media Ltd; 1999. pp. 346-364.
8. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998;51:578–584.
9. Ku JH, Kim ME, Lee NK, Park YH. The prevalence of chronic prostatitis-like symptoms in young men: a community-based survey. Urol Res 2001;29:108–112.
10. Moon TD, Hagen L, Heisey DM. Urinary symptomatology in younger men. Urology 1997;50:700–703.
11. Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int 2000;86:443–448.
12. Shoskes DA, Hakim L, Ghoniem G, Jackson CL. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 2003;169:1406–1410.
13. McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med 2000;133:367–381.
14. Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003;169:1401–1405.
15. Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin, and ofloxacin into the prostate. Int J Urol 1998;5:243–246.
16. Nickel JC, Downey J, Johnston B, Clark J, Canadian Prostatitis. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001;165:1539–1544.
17. Mo KI, Lee KS, Kim DG. Efficacy of combination therapy for patients with chronic prostatitis/chronic pelvic pain syndrome: a prospective study. Korean J Urol 2006;47:536–540.
18. Donker PJ, Ivanovici F, Noach EL. Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br J Urol 1972;44:180–193.
19. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883–887.
20. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 2004;64:881–886.
21. Youn CW, Son KC, Choi HS, Kwon DD, Park K, Ryu SB. Comparison of the efficacy of antibiotic monotherapy and antibiotic plus alpha-blocker combination therapy for patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome. Korean J Urol 2008;49:72–76.
22. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171:1594–1597.
23. Ryu YG, Kim HJ, Park HJ. The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean J Urol 2007;48:858–862.
24. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2008;179:2119–2125.
25. Siller G. Effect of rowatinex capsules on the stone fragments formed by extracorporeal shock-wave lithotripsy. Magyar Urol 1998;10:139–146.
26. Zhou JY, Tang FD, Mao GG, Bian RL. Effect of alpha-pinene on nuclear translocation of NF-kappa B in THP-1 cells. Acta Pharmacol Sin 2004;25:480–484.
27. Park TJ, Park YS, Lee TG, Ha H, Kim KT. Inhibition of acetylcholine-mediated effects by borneol. Biochem Pharmacol 2003;65:83–90.
28. Juergens UR, Stober M, Vetter H. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro. Eur J Med Res 1998;3:508–510.
29. Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and ibuprofen. J Urol 2005;174:375–379.
30. Bak CW, Yoon SJ, Chung H. Effects of an α-blocker and terpene mixture for pain control and spontaneous expulsion of ureter stone. Korean J Urol 2007;48:517–521.